UNSPSC 51101918: Artemotil or beta-arteether

This classification denotes an antimalarial agent with the molecular formula C17H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XGL7GFB9YI, chemically known as 3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-ethoxy-3,6,9-trimethyl-, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12ar*))- but generally known as arteether, which bears US NIH Compound Identifier 72416. European Medicines Agency schedules Artemotil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00596MIG.

UNSPSC 51101918 Artemotil or beta-arteether is a Commodity code that shows minimal alignment with recent state and local procurement activity. The nominal code name refers to a specific antimalarial pharmaceutical compound, but the recent opportunities tagged to this code involve naloxone, medical and first aid supplies, and generic pharmaceuticals — none of which are artemotil or beta-arteether. The code displays a clear mismatch between its stated commodity and actual purchasing patterns in state and local markets.

The recent opportunities on record involve three distinct issuing bodies and geographic regions: Seminole County, Florida procured naloxone and drug deactivation systems through a competitive IFB (posted June 30, 2026, due July 26, 2023); the City of Tampa issued an ITB for medical and first aid supplies for its Fire Department Rescue Division with an estimated contract value of $700,000 and a March 13, 2026 deadline, designated as a sheltered market opportunity for certified Small Local Business Enterprises; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline; and the Texas Health and Human Services Commission posted an RFI for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program with an April 3, 2026 deadline. The code shows no relevant recent activity for artemotil or beta-arteether specifically and should not be relied upon for market intelligence in antimalarial procurement.